THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.6]-C110 ID: TIP-MED-000380

Calcium Citrate Malate (CCM)

Active Ingredient / Scientific Identity: Calcium Citrate Malate • Class: Organic Acid-Independent Soluble Calcium Salt (~21–24% Elemental Calcium; Urinary Citrate Inhibitor of Renal Calculi)

⚖️ Compare Profile
Generic / Entity NameCalcium Citrate Malate (CCM) ([10.6]-C110)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassOrganic Acid-Independent Soluble Calcium Salt (~21–24% Elemental Calcium; Urinary Citrate
Available Dosage FormsOral Film-Coated Tablets: Calcium Citrate 1000–1200 mg or Calcium Citrate Malate (CCM) delivering 250 mg to 50
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: Citrate is metabolised to bicarbonate and increases urinary citrate excretion (which naturally inhibits calcium oxalat
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Calcium Citrate Malate (CCM) (TIP-MED-000380, Reference Code [10.6]-C110) is classified under Vitamins, Minerals & Nutritional Supplements (Ch 10) as a Organic Acid-Independent Soluble Calcium Salt (~21–24% Elemental Calcium; Urinary Citrate Inhibitor of Renal Calculi). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [10.6] (Calcium Citrate / Calcium Citrate Malate (CCM)). Representative Indian Market Examples (Edition 2.7 Ch 10 [10.6], p. 129): Calcitrate, CCM (GSK/Haleon), Milical, Citracal, Shelcal-CT / Ostoshine-CCM, Caldikind — Strengths & Dosage Forms: Oral Film-Coated Tablets: Calcium Citrate 1000–1200 mg or Calcium Citrate Malate (CCM) delivering 250 mg to 500 mg Elemental Calcium (+ Vitamin D3 250–1000 IU, Magnesium, Zinc)
Co-indexed constituent under primary monograph [10.6] (Calcium Citrate / Calcium Citrate Malate (CCM)). Representative Indian Market Examples (Edition 2.7 Ch 10 [10.6], p. 129): Calcitrate, CCM (GSK/Haleon), Milical, Citracal, Shelcal-CT / Ostoshine-CCM, Caldikind — Strengths & Dosage Forms: Oral Film-Coated Tablets: Calcium Citrate 1000–1200 mg or Calcium Citrate Malate (CCM) delivering 250 mg to 500 mg Elemental Calcium (+ Vitamin D3 250–1000 IU, Magnesium, Zinc)
Dosage Forms & Available Strengths:
Oral Film-Coated Tablets: Calcium Citrate 1000–1200 mg or Calcium Citrate Malate (CCM) delivering 250 mg to 500 mg Elemental Calcium (+ Vitamin D3 250–1000 IU, Magnesium, Zinc)
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Organic Acid-Independent Soluble Calcium Salt (~21–24% Elemental Calcium; Urinary Citrate Inhibitor of Renal Calculi) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutritional Supplements (Ch 10): clinical efficacy is mediated via Organic Acid-Independent Soluble Calcium Salt (~21–24% Elemental Calcium; Urinary Citrate Inhibitor of Renal Calculi) for Calcium supplementation in elderly patients with age-related achlorhydria, patients on chronic Proton Pump Inhibitors (Pantoprazole/Omeprazole) or H2-blockers, patients with chronic constipation, and patients with a history of renal calculi (kidney stones)..

4. Therapeutic Indications & Evidence-Supported Uses

  • Calcium supplementation in elderly patients with age-related achlorhydria, patients on chronic Proton Pump Inhibitors (Pantoprazole/Omeprazole) or H2-blockers, patients with chronic constipation, and patients with a history of renal calculi (kidney stones)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: 250 mg to 500 mg elemental calcium once or twice daily. Follow physician prescription.

Administration & Meal Timing: May be taken WITH or WITHOUT food! (Unlike Calcium Carbonate, Calcium Citrate and CCM are water-soluble and do NOT require gastric acid for intestinal absorption!). | Once or twice daily (typically after lunch and/or dinner, spaced ≥4 hours away from morning Levothyroxine and ≥2 hours from Iron/Antibiotics).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [10.6].
Metabolism & Biotransformation:
Renal: Citrate is metabolised to bicarbonate and increases urinary citrate excretion (which naturally inhibits calcium oxalate stone crystallization in the urine!); however, in advanced CKD (Stages 4–5), avoid combining with aluminium salts and note that calcium citrate is less effective as a phosphate binder than calcium carbonate. Hepatic: Safe.
Elimination & Renal Adjustment:
Renal: Citrate is metabolised to bicarbonate and increases urinary citrate excretion (which naturally inhibits calcium oxalate stone crystallization in the urine!); however, in advanced CKD (Stages 4–5), avoid combining with aluminium salts and note that calcium citrate is less effective as a phosphate binder than calcium carbonate. Hepatic: Safe.
Hepatic Impairment Considerations:
Renal: Citrate is metabolised to bicarbonate and increases urinary citrate excretion (which naturally inhibits calcium oxalate stone crystallization in the urine!); however, in advanced CKD (Stages 4–5), avoid combining with aluminium salts and note that calcium citrate is less effective as a phosphate binder than calcium carbonate. Hepatic: Safe.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in hypercalcaemia and severe hypercalciuria. CRITICAL CKD ALUMINIUM INTERACTION: Citrate salts markedly increase the intestinal absorption of Aluminium! Never co-administer Calcium Citrate with Aluminium-containing antacids (Digene/Gelusil) or Sucralfate in patients with Chronic Kidney Disease (precipitates acute aluminium neurotoxicity/encephalopathy and osteomalacia!).

Key Clinical Precautions: Renal: Citrate is metabolised to bicarbonate and increases urinary citrate excretion (which naturally inhibits calcium oxalate stone crystallization in the urine!); however, in advanced CKD (Stages 4–5), avoid combining with aluminium salts and note that calcium citrate is less effective as a phosphate binder than calcium carbonate. Hepatic: Safe.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Very well tolerated; significantly lower rates of constipation, abdominal bloating, and flatulence than Calcium Carbonate (because no CO2 gas is generated in the stomach!).
  • Hypercalcaemia (if combined with excessive Vitamin D/thiazides), aluminium toxicity if combined with Al-antacids in CKD.
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Same chelation interactions as Calcium Carbonate with Levothyroxine (space ≥4 hours), Fluoroquinolones, Tetracyclines, Oral Iron, and Bisphosphonates (space ≥2–4 hours)! Enhances intestinal Aluminium absorption from antacids/sucralfate
    • Safe and fully absorbed alongside PPIs (Pantoprazole/Rabeprazole)

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [10.6].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: Explain to elderly patients who complain of severe constipation or gas from standard Calcium Carbonate (Shelcal), or who take daily acidity capsules (Pantoprazole), that Calcium Citrate / CCM absorbs smoothly without needing stomach acid, does not produce stomach gas, and helps protect against kidney stones.
    • Meal & Clock Timing Instruction: May be taken WITH or WITHOUT food! (Unlike Calcium Carbonate, Calcium Citrate and CCM are water-soluble and do NOT require gastric acid for intestinal absorption!). (Once or twice daily (typically after lunch and/or dinner, spaced ≥4 hours away from morning Levothyroxine and ≥2 hours from Iron/Antibiotics).)
    • Missed Dose Protocol: Take as soon as remembered (keeping ≥2–4 hours from interacting medications); do not double.
    • Geriatric Dispensing Pearl: Preferred calcium formulation for elderly CGHS beneficiaries due to high prevalence of gastric hypochlorhydria, concurrent PPI therapy, and chronic constipation.

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: Calcium Citrate 1000–1200 mg or Calcium Citrate Malate (CCM) delivering 250 mg to 500 mg Elemental Calcium (+ Vitamin D3 250–1000 IU, Magnesium, Zinc)

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.